Voluntary disclosure of the announcement that the company was selected as the sixth batch of specialized, special and new “little giant” enterprises at the national level
Voluntary Disclosure Notice Regarding Acceptance of Clinical Trial Applications for the Treatment of Extensive Small Cell Lung Cancer with Theoroni Capsules
Voluntary disclosure of the announcement regarding the approval of the indications for the use of empagliflozin and metformin hydrochloride in the treatment of type 2 diabetes.
Announcement on the results of convertible bonds and changes in shareholding
Announcement regarding the interest payment for Weichip Convertible Bonds in 2024.
CSI Securities Co., Ltd.'s entrusted management report on Shenzhen Chipscreen Biosciences Co., Ltd.'s issuance of convertible corporate bonds to unspecified objects (2023). Bonds.
Announcement about not adjusting the conversion price of "Wichips Convertible Bonds" downward.
In 2022, Shenzhen Chipscreen Biosciences Co., Ltd. issued convertible corporate bonds to unspecified investors. The tracking rating report is for 2024.
Announcement regarding the credit rating results of the Weichip Convertible Bond Tracking.
Announcement for the Expected Fulfillment of Conversion Price Adjustment Conditions regarding 'Microchip Convertible Bonds'.
Voluntary disclosure of announcements regarding the company's drugs to be included in breakthrough therapeutic categories
Announcement on the adjustment of the conversion price of the convertible corporate bond “Microchip Convertible Bonds” and the suspension and resumption of trading
Notice on Response to the 2023 Annual Report Information Disclosure Regulatory Inquiry Letter
Voluntary Disclosure Notice Concerning Acceptance of Sidabendamide Clinical Trial Application for Colorectal Cancer III
Announcement on the results of the resale of “Microchip Convertible Bonds”
Third indicative announcement on the option to resell “Microchip Bonds Converter”
Voluntary disclosure announcement on approval for marketing of sidabendamide combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
Second indicative announcement on the option to resell “Microchip Bonds Converter”
First indicative announcement on the option to resell “Microchip Bonds Converter”
Announcement on the optional resale of “Microchip Bonds Converter”
No Data